Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

 
Thumbnail
View/Open
Author
Lewis, Huw D.
Liddle, John
Coote, Jim E.
Atkinson, Stephen J.
Barker, Michael D.
Bax, Benjamin, D.
Bicker, Kevin L.
Bingham, Ryan P.
Campbell, Matthew
Chen, Yu Hua
Chung, Chun-wa
Craggs, Peter D.
Davis, Rob P.
Eberhard, Dirk
Joberty, Gerard
Lind, Kenneth E.
Locke, Kelly
Maller, Claire
Patten, Chris
Polyakova, Oxana
Rise, Cecil E.
Rüdiger, Martin
Sheppard, Robert J.
Slade, Daniel J.
Thomas, Pamela
Thorpe, Jim
Yao, Gang
Drewes, Gerard
Thompson, Paul R.
Prinjha, Rab K.
Wilson, David M.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/nchembio.1735
Metadata
Show full item record
Citation
Lewis, H. D., J. Liddle, J. E. Coote, S. J. Atkinson, M. D. Barker, B. D. Bax, K. L. Bicker, et al. 2015. “Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.” Nature chemical biology 11 (3): 189-191. doi:10.1038/nchembio.1735. http://dx.doi.org/10.1038/nchembio.1735.
Abstract
PAD4 has been strongly implicated in the pathogenesis of autoimmune, cardiovascular and oncological diseases, through clinical genetics and gene disruption in mice. Novel, selective PAD4 inhibitors binding to a calcium-deficient form of the PAD4 enzyme have, for the first time, validated the critical enzymatic role of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation. The therapeutic potential of PAD4 inhibitors can now be explored.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397581/pdf/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:22857023

Collections